2026-07-21T08:44:11Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/169522025-11-28T13:00:57Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Bernardo, Lorena author Solana, Jose Carlos author Sanchez Herrero, Carmen author Torres Garcia, Ana Maria author Reyes-Cruz, Eder Yaveth author Carrillo, Eugenia author Moreno, Javier author 2023 Background: Immunosuppression is a major risk factor for the development of visceral leishmaniasis (VL). The number of patients receiving immunosuppressant drugs such as TNF antagonist (anti-TNF) and methotrexate (MTX) is increasing. In these patients, VL is more severe, their response to treatment poorer, and they are at higher risk of relapse, a consequence (largely) of the poor and inappropriate immune response they develop. Objectives: To examine the effect of immunosuppressive treatment on the host immune response and thus gain insight into the reduced efficacy of pentavalent antimonials in these patients. Experiments were performed using BALB/c mice immunosuppressed with anti-TNF or MTX, infected with Leishmania infantum promastigotes, and then treated with Glucantime® at clinical doses. Results: Immunosuppression with both agents impeded parasite elimination from the spleen and bone marrow. Low pro-inflammatory cytokine production by CD4+ and CD8+ T cells was detected, along with an increase in PD-1 and IL-10 expression by B and T cells in the immunosuppressed groups after treatment. Conclusion: The immunosuppressed mice were unable to develop specific cellular immunity to the parasite, perhaps explaining the greater risk of VL relapse seen in pharmacologically immunosuppressed human patients. Front Immunol. 2023 Dec 1:14:1285943. 10.3389/fimmu.2023.1285943 1664-3224 Frontiers in immunology http://hdl.handle.net/20.500.12105/16952 Visceral leishmaniasis Immunosuppression Immunosuppressants BALB/c mice TNF antagonist Methotrexate Glucantime® Immunosuppressants alter the immune response associated with Glucantime® treatment for Leishmania infantum infection in a mouse model